GO:0005123 death receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005123 (death receptor binding) is a molecular function describing binding to a member of the death receptor (DR) family, which belongs to the tumor necrosis factor receptor superfamily and carries a cytoplasmic death domain (DD).
• Death receptor binding is the first step in assembling death-inducing signaling complexes (DISCs) that can trigger caspase-8 activation, apoptosis, necroptosis, or pyroptosis depending on cellular context.
• Key death receptors include FAS (CD95), TNFR1, DR3, DR5, DR6, and EDAR; their adaptors and modifiers include FADD, TRADD, TRAF2, RIPK1, RIPK3, ZBP1, and calmodulin.
• Dysregulated death receptor binding contributes to cancer, acute kidney injury, intestinal inflammation, and inflammatory/necroptotic disease states.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test whether candidate death-receptor-binding proteins are causal in these pathways.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to dissect death receptor binding mechanisms with publication-grade reproducibility.
Description
GO:0005123, death receptor binding, is a molecular function that captures the physical interaction between a protein and a member of the death receptor (DR) family. Death receptors are a subset of the tumor necrosis factor receptor superfamily defined by a cytoplasmic region of approximately 80 residues known as the death domain (DD), which enables them to nucleate signaling complexes that control cell death and inflammation. Because this binding event sits at the top of several clinically important pathways, it is a central node for researchers studying apoptosis, necroptosis, pyroptosis, and inflammatory signaling. The functional consequences of death receptor binding are context-dependent. For example, binding of adaptor proteins such as TRADD and TRAF2 to DR3 occurs independently of its natural ligand TL1A, showing that intracellular death receptor interactions can be ligand-independent. In other settings, death receptor 6 (DR6) binding activates caspase-8 to drive GSDMC-dependent pyroptosis, while ZBP1 engagement can promote RIPK3-mediated necroptosis and RIPK1 kinase activity-independent apoptosis. These examples illustrate why death receptor binding must be studied with precise, causally informative models rather than inferred from correlation. For biomedical researchers, GO:0005123 provides a controlled vocabulary to annotate proteins that directly bind death receptors, including adaptors, modifiers, and viral or synthetic binders. Accurate annotation supports pathway reconstruction, target prioritization, and the design of CRISPR experiments that test the role of each binding partner in disease-relevant cell states.
death receptor binding At A Glance
| GO ID | GO:0005123 |
|---|---|
| GO term | death receptor binding |
| Ontology | molecular_function |
| Definition | Binding to a member of the death receptor (DR) family. The DR family falls within the tumor necrosis factor receptor superfamily and is characterized by a cytoplasmic region of ~80 residues termed the death domain (DD). |
| Synonym | APO binding; death receptor adaptor protein activity; death receptor-associated factor activity; death receptor interacting protein activity; death receptor ligand; DR binding; EDAR binding; FAS binding; KILLER binding; NGFR binding; TNFR1 binding; TRAIL binding |
| Major function | Mediates assembly of death-inducing signaling complexes (DISCs) and related signaling platforms that control apoptosis, necroptosis, pyroptosis, and inflammatory gene expression. |
| Representative receptors | FAS (CD95), TNFR1, DR3, DR5, DR6, EDAR. |
| Representative binders | FADD, TRADD, TRAF2, RIPK1, RIPK3, ZBP1, calmodulin. |
| Disease relevance | Cancer, acute kidney injury, intestinal inflammation, and necroptotic/inflammatory disorders. |
What Is GO:0005123?
In plain terms, GO:0005123 describes the ability of a protein to bind to a death receptor. The QuickGO definition states that this function is binding to a member of the death receptor (DR) family, which falls within the tumor necrosis factor receptor superfamily and is characterized by a cytoplasmic region of about 80 residues called the death domain (DD). This molecular function is therefore narrower than general TNF receptor binding: it specifically refers to interactions with receptors that contain a death domain and can assemble death-inducing signaling complexes. Examples include FAS binding, TNFR1 binding, TRAIL/DR5 binding, DR3 binding, and EDAR binding, as reflected in the synonym list.
Why Is death receptor binding Important in Cell Biology?
Death receptor binding is important because it is the molecular trigger that converts extracellular or intracellular cues into cell fate decisions. When a protein binds a death receptor, it can nucleate a DISC that activates caspase-8, leading to apoptosis, or it can redirect signaling toward RIPK3-dependent necroptosis or GSDMC-dependent pyroptosis. Because these outcomes are central to cancer cell death, tissue injury, and inflammation, the binding function encoded by GO:0005123 is a high-value target for mechanistic studies and therapeutic hypothesis testing.
• Defines the first molecular step in DISC assembly and caspase-8 activation.
• Controls whether a cell undergoes apoptosis, necroptosis, or pyroptosis.
• Ligand-independent intracellular binding, as shown for DR3-TRADD/TRAF2, expands the regulatory logic of death receptors.
• Modulates inflammatory signaling through TNFR1 internalization and ZBP1-RIPK3 axes.
• Implicated in acute kidney injury via a YY1-KIM1-DR5 axis.
• Relevant to cancer therapy because DR5 and DR6 binding can drive tumor cell death.
• Provides annotation targets for genome-wide CRISPR screens of cell death pathways.
• Supports development of biologics or small molecules that mimic or block death receptor binding.
• Enables cross-species comparison of death domain-containing receptors and their adaptors.
• Underpins biomarker discovery for inflammatory and injury-related diseases.
Molecular Mechanism of death receptor binding
Death receptor recognition and death domain docking
In simple terms: A binding protein recognizes the death receptor and docks onto its intracellular death domain.
Death receptors share a cytoplasmic death domain (DD) of about 80 residues that serves as the docking surface for adaptors and modifiers. Binding to this region is the defining feature of GO:0005123 and is required for recruitment of downstream signaling components. For example, DR3 can bind intracellular TRADD and TRAF2 independently of its natural ligand TL1A, demonstrating that death domain-proximal interactions can occur in a ligand-independent manner. Similarly, calmodulin binds DR5 within the death-inducing signaling complex in breast cancer cells, showing that non-classical binders can also engage death receptors.
DISC assembly and caspase-8 activation
In simple terms: Once bound, proteins assemble a platform that switches on caspase-8.
Death receptor binding nucleates the death-inducing signaling complex (DISC), which recruits and activates caspase-8. In DR6-activated pyroptosis, this leads to GSDMC-dependent membrane pore formation and cell lysis. In breast cancer cells, calmodulin binding to DR5 modulates DISC formation, illustrating that accessory binders can tune caspase-8 activation. The composition and stoichiometry of the DISC therefore determine whether the cell commits to death and which death program is executed.
RIPK1, RIPK3, and ZBP1 crosstalk
In simple terms: Death receptor binding can also steer cells toward necroptosis through RIP kinases and ZBP1.
Beyond caspase-8, death receptor binding interfaces with RIPK1, RIPK3, and ZBP1 to control necroptosis and inflammation. STING can induce ZBP1-mediated necroptosis independently of TNFR1 and FADD, showing that death receptor binding is not the only route to RIPK3 activation but can cooperate with innate immune sensors. ZBP1 causes inflammation by inducing RIPK3-mediated necroptosis and RIPK1 kinase activity-independent apoptosis. The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation, highlighting how death domain interactions act as checkpoints.
Regulation by internalization and cellular context
In simple terms: How much receptor is on the surface and where it traffics changes the outcome of binding.
Death receptor binding is regulated by receptor internalization and trafficking. EFHD2 suppresses intestinal inflammation by blocking TNFR1 internalization and cell death, showing that access to the receptor is a control point. In acute kidney injury, a YY1-KIM1-DR5 axis regulates disease progression, linking transcriptional control of a death receptor to injury outcomes. These examples show that the functional readout of GO:0005123 depends on receptor abundance, localization, and the cellular context in which binding occurs.
Ligand-dependent versus ligand-independent binding
In simple terms: Some binders need the ligand, others do not.
Classical models emphasize ligand-induced trimerization of death receptors, but recent work shows that intracellular binding can be ligand-independent. DR3 binding to TRADD and TRAF2 occurs without TL1A, indicating that death receptor adaptor recruitment can be constitutive or regulated by other cues. This distinction matters for experimental design because blocking ligand binding may not abolish all GO:0005123-dependent signaling.
Key Genes Involved in GO:0005123 death receptor binding
The following genes and proteins are central to death receptor binding (GO:0005123) and are frequently manipulated in mechanistic studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FAS | Death receptor that binds FADD and initiates apoptosis | Model for DISC assembly and caspase-8 activation |
| TNFRSF1A (TNFR1) | Death receptor for TNF-alpha; binds TRADD and RIPK1 | Target for inflammation and internalization studies |
| TNFRSF25 (DR3) | Death receptor that binds TRADD and TRAF2 | Ligand-independent adaptor recruitment |
| TNFRSF10B (DR5) | TRAIL receptor that binds calmodulin and DISC components | Breast cancer DISC studies |
| TNFRSF21 (DR6) | Death receptor 6 that activates caspase-8 | GSDMC-dependent pyroptosis |
| FADD | Adaptor that binds death receptors and recruits caspase-8 | Core DISC component |
| TRADD | Adaptor that binds TNFR1 and DR3 | Ligand-independent DR3 binding |
| TRAF2 | E3 ligase/adaptor that binds DR3 and TNFR1 | Death receptor signaling modulation |
| RIPK1 | Kinase with death domain that binds death receptors | Checkpoint for necroptosis and apoptosis |
| RIPK3 | Kinase that executes necroptosis downstream of ZBP1 | Necroptosis effector |
| ZBP1 | Sensor that induces RIPK3-mediated necroptosis | Innate immune crosstalk with death receptors |
| CALM1/CALM2/CALM3 | Calmodulin binds DR5 in the DISC | Accessory regulation of death receptor signaling |
| EFHD2 | Blocks TNFR1 internalization | Intestinal inflammation suppression |
| KIM1 (HAVCR1) | Regulates DR5 in acute kidney injury | YY1-KIM1-DR5 axis |
| YY1 | Transcription factor controlling KIM1-DR5 axis | Acute kidney injury progression |
| STING (TMEM173) | Induces ZBP1-mediated necroptosis | TNFR1/FADD-independent necroptosis |
| TRIF (TICAM1) | Adaptor restrained by RIPK1 death domain | Inflammation and cell death control |
How Is death receptor binding Regulated?
Death receptor binding is regulated at multiple levels. Receptor internalization controls access of intracellular binders to TNFR1, as shown by EFHD2 blocking internalization and suppressing intestinal inflammation. Transcriptional control of death receptors, such as the YY1-KIM1-DR5 axis in acute kidney injury, changes the abundance of available receptor for binding. At the signaling level, the RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation, acting as a brake on death receptor-associated pathways. In addition, ligand-independent binding of TRADD and TRAF2 to DR3 shows that adaptor recruitment can be uncoupled from ligand availability. Together, these mechanisms determine whether death receptor binding leads to apoptosis, necroptosis, pyroptosis, or inflammatory gene expression.
death receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFRSF21 (DR6) | GSDMC-dependent pyroptosis in cancer | Knockout and point-mutation cancer cell lines |
| TNFRSF10B (DR5) | Breast cancer DISC signaling | Knock-in tagged DR5 and calmodulin-binding mutants |
| TNFRSF1A (TNFR1) | Intestinal inflammation | EFHD2 knockout intestinal epithelial cells |
| HAVCR1 (KIM1) / YY1 | Acute kidney injury | YY1 or KIM1 knockout renal tubular cells |
| ZBP1 / RIPK3 | Necroptotic inflammation | ZBP1 or RIPK3 knockout macrophages |
Cancer and cell death evasion
Death receptor binding is directly relevant to cancer because DR5 and DR6 engagement can activate caspase-8 and execute cell death programs. In breast cancer cells, calmodulin binding to DR5 within the DISC modulates death-inducing signaling, suggesting that accessory binders can influence therapeutic responses. DR6-activated caspase-8 induces GSDMC-dependent pyroptosis, providing a non-apoptotic death mechanism that could be exploited in tumors. These findings make death receptor binding a target for strategies that aim to restore or amplify cell death in cancer.
Acute kidney injury
A renal YY1-KIM1-DR5 axis regulates the progression of acute kidney injury, linking a death receptor and its regulatory network to tubular injury. Because DR5 is a death receptor, changes in its expression or binding partners can shift the balance between survival and death in kidney epithelial cells. This axis provides a disease-relevant context in which to test GO:0005123-dependent mechanisms.
Intestinal inflammation and inflammatory disease
EFHD2 suppresses intestinal inflammation by blocking TNFR1 internalization and cell death, showing that the subcellular trafficking of a death receptor controls inflammatory outcomes. ZBP1 causes inflammation by inducing RIPK3-mediated necroptosis and RIPK1 kinase activity-independent apoptosis, and the RIPK1 death domain restrains ZBP1- and TRIF-mediated inflammation. These studies connect death receptor binding and death domain interactions to mucosal and systemic inflammatory disease.
Innate immune crosstalk and necroptosis
STING induces ZBP1-mediated necroptosis independently of TNFR1 and FADD, demonstrating that death receptor binding pathways intersect with cytosolic innate immune sensing. This crosstalk expands the disease contexts in which GO:0005123-related proteins are relevant, including infections and sterile inflammation.
From death receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate binder required for death receptor-induced apoptosis? | CRISPR knockout of the candidate gene in a death receptor-expressing cell line |
| Does a specific death domain residue mediate binding? | Point mutation of the death domain in the receptor or binder |
| Can a tagged binder be tracked in the DISC? | Knock-in of an epitope tag at the endogenous locus |
| Does overexpression of a binder sensitize cells to death? | Doxycycline-inducible overexpression cell line |
| Which genes modify death receptor binding sensitivity? | Genome-wide CRISPR library screening |
| Does ligand-independent binding occur in cells? | Ligand-deficient knockout plus co-immunoprecipitation |
How to Study the death receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between binder and death receptor | Confirm GO:0005123 binding |
| Proximity labeling | Spatially restricted interactome | Discover new death receptor binders |
| Caspase-8 activity assay | Activation of initiator caspase | DISC functional readout |
| LDH release / viability | Cell death and membrane integrity | Pyroptosis and necroptosis quantification |
| Genome-wide CRISPR screen | Genes modifying death receptor phenotypes | Pathway discovery |
| Live-cell imaging | Receptor internalization and complex assembly | Trafficking regulation |
| Phospho-RIPK1/RIPK3 immunoblot | Necroptotic kinase activation | ZBP1-RIPK3 axis validation |
| Transcriptomics (RNA-seq) | Gene expression changes after binding | Context-dependent outcome mapping |
Co-immunoprecipitation and proximity labeling
Co-immunoprecipitation remains the standard method to detect physical binding between a candidate protein and a death receptor, and it was used to show ligand-independent DR3 binding to TRADD and TRAF2. Proximity labeling can complement co-IP by capturing transient or low-affinity interactions in living cells. When combined with knockout controls, these methods distinguish direct binding from indirect complex association.
Cell death assays and caspase activation
Because death receptor binding often leads to caspase-8 activation, apoptosis, necroptosis, or pyroptosis, functional readouts such as caspase activity, viability, and pyroptosis markers are essential. DR6-activated caspase-8 and GSDMC-dependent pyroptosis were demonstrated with such assays. ZBP1-mediated necroptosis and RIPK1-dependent apoptosis require parallel measurement of multiple death modalities.
CRISPR screening and functional genomics
Genome-wide CRISPR screens can identify genes that modify death receptor binding-dependent phenotypes. Screens have been used to dissect necroptotic and inflammatory pathways involving ZBP1, RIPK3, and STING. Hits from these screens can then be validated with focused knockout or point-mutation models.
Imaging and trafficking analysis
Live-cell imaging of receptor internalization and complex assembly is important because trafficking controls access of binders to death receptors. EFHD2 was shown to suppress intestinal inflammation by blocking TNFR1 internalization, a process best visualized with imaging and surface-labeling approaches. Tagged knock-in lines enable tracking of endogenous receptors and binders without overexpression artifacts.
How CRISPR Can Be Used to Study GO:0005123 death receptor binding
Knockout
CRISPR knockout of a candidate death receptor or binder is the most direct way to test necessity. For example, knockout of ZBP1 or RIPK3 clarifies necroptotic signaling downstream of death receptor binding. Knockout of EFHD2 or KIM1 can reveal their roles in TNFR1 internalization and the YY1-KIM1-DR5 axis, respectively. Knockout models should be validated for loss of protein and for absence of compensatory upregulation of related family members.
Point Mutation
Point mutations in the death domain or in the binding interface can separate binding from downstream signaling. The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death, so mutations that disrupt this domain can reveal checkpoint functions. Point mutants of DR3 or its adaptors can test whether ligand-independent TRADD/TRAF2 binding uses the same surface as ligand-dependent activation. These models are essential for causal claims about GO:0005123.
Knock-in
Knock-in of epitope tags, fluorescent proteins, or disease-relevant alleles allows endogenous-level study of death receptor binding. Tagged DR5 knock-in can be used to isolate the DISC and identify associated proteins such as calmodulin. Knock-in of point mutations identified in patients or screens can test their impact on death receptor binding and cell fate in a physiological context.
Overexpression
Overexpression models are useful for gain-of-function questions, such as whether increased levels of a binder sensitize cells to death receptor-induced pyroptosis or apoptosis. Inducible overexpression avoids confounding from chronic selection and allows time-resolved analysis of DISC assembly. Overexpression results should be interpreted alongside knockout data to avoid artifacts from non-physiological protein levels.
How EDITGENE Supports death receptor binding Research
Researchers studying death receptor binding-related genes often need to determine whether a candidate gene is causally involved in apoptosis, necroptosis, pyroptosis, or inflammation, rather than merely correlated with these phenotypes. EDITGENE provides the CRISPR cell models and screening services required to move from hypothesis to publication-grade evidence.
Contact EDITGENE today to design your custom CRISPR model for death receptor binding research.
Frequently Asked Questions About death receptor binding
What is GO:0005123 death receptor binding?
GO:0005123 is a molecular function describing binding to a member of the death receptor (DR) family, which belongs to the tumor necrosis factor receptor superfamily and contains a cytoplasmic death domain of about 80 residues.
What genes are involved in death receptor binding?
Key genes include FAS, TNFRSF1A (TNFR1), TNFRSF25 (DR3), TNFRSF10B (DR5), TNFRSF21 (DR6), FADD, TRADD, TRAF2, RIPK1, RIPK3, ZBP1, calmodulin genes, EFHD2, KIM1, YY1, STING, and TRIF.
What is the death domain in death receptors?
The death domain is a cytoplasmic region of approximately 80 residues that defines the death receptor family and serves as the docking surface for adaptors and other binding proteins.
How does death receptor binding lead to apoptosis?
Binding nucleates the death-inducing signaling complex (DISC), which recruits and activates caspase-8, initiating apoptosis or related death programs.
Can death receptor binding occur without ligand?
Yes. DR3 binding to intracellular TRADD and TRAF2 occurs independently of its natural ligand TL1A, showing that some death receptor interactions are ligand-independent.
What is the role of RIPK1 in death receptor binding?
The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation, acting as a checkpoint in death receptor-associated signaling.
How is death receptor binding studied in the lab?
Common methods include co-immunoprecipitation, proximity labeling, caspase activity assays, cell death assays, live-cell imaging, and CRISPR screens.
Which diseases are linked to death receptor binding?
Death receptor binding is linked to cancer, acute kidney injury, intestinal inflammation, and necroptotic/inflammatory conditions.
What CRISPR models are used for death receptor binding research?
Knockout, point-mutation, knock-in/tagged knock-in, and overexpression models are used to test necessity, sufficiency, and mechanism.
Why is death receptor binding important for drug discovery?
Because it controls cell death and inflammation, modulating death receptor binding could influence cancer therapy and inflammatory disease treatment.
Conclusion
GO:0005123 death receptor binding is a compact but powerful molecular function that sits at the origin of apoptosis, necroptosis, pyroptosis, and inflammatory signaling. The literature shows that binding can be ligand-dependent or ligand-independent, that it is regulated by receptor trafficking and transcriptional control, and that its outcomes depend on adaptors such as FADD, TRADD, TRAF2, RIPK1, RIPK3, and ZBP1. For researchers, the priority is causal evidence. CRISPR knockout, point-mutation, knock-in, and overexpression models, combined with functional death assays and screening, provide the experimental rigor needed to connect a candidate binder to a disease-relevant phenotype. EDITGENE supports each of these steps with validated cell models and bioinformatics, helping teams generate publication-ready data on death receptor binding.
References
- 1. Zhang JY et al.. 2021. The metabolite α-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-8.. Cell Res 31(9):980-997 PMID: 34012073
- 2. Kelepouras K et al.. 2025. STING induces ZBP1-mediated necroptosis independently of TNFR1 and FADD.. Nature 647(8090):735-746 PMID: 40834903
- 3. Sun W et al.. 2026. Binding of death receptor 3 (DR3) to intracellular TRADD and TRAF2 is independent of its natural ligand, TL1A.. J Immunol 215(7) PMID: 42522260
- 4. Yang C et al.. 2023. A renal YY1-KIM1-DR5 axis regulates the progression of acute kidney injury.. Nat Commun 14(1):4261 PMID: 37460623
- 5. Wu J et al.. 2024. EFHD2 suppresses intestinal inflammation by blocking intestinal epithelial cell TNFR1 internalization and cell death.. Nat Commun 15(1):1282 PMID: 38346956
- 6. Koerner L et al.. 2024. ZBP1 causes inflammation by inducing RIPK3-mediated necroptosis and RIPK1 kinase activity-independent apoptosis.. Cell Death Differ 31(7):938-953 PMID: 38849574
- 7. Fancy RM et al.. 2017. Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells.. J Cell Biochem 118(8):2285-2294 PMID: 28092099
- 8. Imai T et al.. 2024. The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation.. Immunity 57(7):1497-1513.e6 PMID: 38744293
